Mireca Medicines GmbH is an expanding, preclinical stage company pioneering the development of proprietary cyclic guanosine monophosphate (cGMP)-analogs and drug delivery technologies to treat diseases caused by a dysregulation of cGMP, affecting protein kinase G. Visite our website.